Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy: Update of the Italian Expert Recommendations

Carmine Pinto, Carlo A. Barone, Giampiero Girolomoni, Elvio G. Russi, Marco C. Merlano, Daris Ferrari, Evaristo Maiello

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

OBJECTIVES:: Cetuximab was shown in phase III clinical trials to improve chemotherapy efficacy in patients with advanced colorectal and head-neck cancer. Appropriate management of skin reactions associated with epidermal growth factor receptor inhibitor therapy is necessary to allow adequate drug compliance and to improve patient quality of life and outcomes. METHODS:: The RAND/UCLA Appropriateness Method was used by a group of experts to produce new Italian recommendations on the management of skin reactions in this setting. Statements were generated on the basis of an updated systematic review of the literature and rated twice by a panel of 38 expert physicians. A meeting of the panel was held after the first rating session. RESULTS:: Skin reactions included acneiformic rash, skin dryness (xerosis), pruritus, paronychia, hair abnormalities, mucositis, and increased growth of eyelashes or facial hair. Updates of the previous recommendations on the prevention and treatment of each type of reaction were proposed. CONCLUSIONS:: This updated Expert Opinion focuses on how to assess and correctly grade skin reactions according to the latest National Cancer Institute Common Terminology Criteria for Adverse Events and on how to manage these adverse events in clinical practice.

Original languageEnglish
Pages (from-to)407-15
Number of pages9
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume39
Issue number4
DOIs
Publication statusAccepted/In press - Apr 13 2016

Fingerprint

Radiotherapy
Drug Therapy
Skin
Hair
Paronychia
Eyelashes
Phase III Clinical Trials
Mucositis
National Cancer Institute (U.S.)
Expert Testimony
Therapeutics
Pruritus
Head and Neck Neoplasms
Exanthema
Epidermal Growth Factor Receptor
Terminology
Quality of Life
Physicians
Cetuximab
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy : Update of the Italian Expert Recommendations. / Pinto, Carmine; Barone, Carlo A.; Girolomoni, Giampiero; Russi, Elvio G.; Merlano, Marco C.; Ferrari, Daris; Maiello, Evaristo.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 39, No. 4, 13.04.2016, p. 407-15.

Research output: Contribution to journalArticle

@article{3d8d6ed7d9d44546be9eb480b2ff58cf,
title = "Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy: Update of the Italian Expert Recommendations",
abstract = "OBJECTIVES:: Cetuximab was shown in phase III clinical trials to improve chemotherapy efficacy in patients with advanced colorectal and head-neck cancer. Appropriate management of skin reactions associated with epidermal growth factor receptor inhibitor therapy is necessary to allow adequate drug compliance and to improve patient quality of life and outcomes. METHODS:: The RAND/UCLA Appropriateness Method was used by a group of experts to produce new Italian recommendations on the management of skin reactions in this setting. Statements were generated on the basis of an updated systematic review of the literature and rated twice by a panel of 38 expert physicians. A meeting of the panel was held after the first rating session. RESULTS:: Skin reactions included acneiformic rash, skin dryness (xerosis), pruritus, paronychia, hair abnormalities, mucositis, and increased growth of eyelashes or facial hair. Updates of the previous recommendations on the prevention and treatment of each type of reaction were proposed. CONCLUSIONS:: This updated Expert Opinion focuses on how to assess and correctly grade skin reactions according to the latest National Cancer Institute Common Terminology Criteria for Adverse Events and on how to manage these adverse events in clinical practice.",
author = "Carmine Pinto and Barone, {Carlo A.} and Giampiero Girolomoni and Russi, {Elvio G.} and Merlano, {Marco C.} and Daris Ferrari and Evaristo Maiello",
year = "2016",
month = "4",
day = "13",
doi = "10.1097/COC.0000000000000291",
language = "English",
volume = "39",
pages = "407--15",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy

T2 - Update of the Italian Expert Recommendations

AU - Pinto, Carmine

AU - Barone, Carlo A.

AU - Girolomoni, Giampiero

AU - Russi, Elvio G.

AU - Merlano, Marco C.

AU - Ferrari, Daris

AU - Maiello, Evaristo

PY - 2016/4/13

Y1 - 2016/4/13

N2 - OBJECTIVES:: Cetuximab was shown in phase III clinical trials to improve chemotherapy efficacy in patients with advanced colorectal and head-neck cancer. Appropriate management of skin reactions associated with epidermal growth factor receptor inhibitor therapy is necessary to allow adequate drug compliance and to improve patient quality of life and outcomes. METHODS:: The RAND/UCLA Appropriateness Method was used by a group of experts to produce new Italian recommendations on the management of skin reactions in this setting. Statements were generated on the basis of an updated systematic review of the literature and rated twice by a panel of 38 expert physicians. A meeting of the panel was held after the first rating session. RESULTS:: Skin reactions included acneiformic rash, skin dryness (xerosis), pruritus, paronychia, hair abnormalities, mucositis, and increased growth of eyelashes or facial hair. Updates of the previous recommendations on the prevention and treatment of each type of reaction were proposed. CONCLUSIONS:: This updated Expert Opinion focuses on how to assess and correctly grade skin reactions according to the latest National Cancer Institute Common Terminology Criteria for Adverse Events and on how to manage these adverse events in clinical practice.

AB - OBJECTIVES:: Cetuximab was shown in phase III clinical trials to improve chemotherapy efficacy in patients with advanced colorectal and head-neck cancer. Appropriate management of skin reactions associated with epidermal growth factor receptor inhibitor therapy is necessary to allow adequate drug compliance and to improve patient quality of life and outcomes. METHODS:: The RAND/UCLA Appropriateness Method was used by a group of experts to produce new Italian recommendations on the management of skin reactions in this setting. Statements were generated on the basis of an updated systematic review of the literature and rated twice by a panel of 38 expert physicians. A meeting of the panel was held after the first rating session. RESULTS:: Skin reactions included acneiformic rash, skin dryness (xerosis), pruritus, paronychia, hair abnormalities, mucositis, and increased growth of eyelashes or facial hair. Updates of the previous recommendations on the prevention and treatment of each type of reaction were proposed. CONCLUSIONS:: This updated Expert Opinion focuses on how to assess and correctly grade skin reactions according to the latest National Cancer Institute Common Terminology Criteria for Adverse Events and on how to manage these adverse events in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84963579043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963579043&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000291

DO - 10.1097/COC.0000000000000291

M3 - Article

AN - SCOPUS:84963579043

VL - 39

SP - 407

EP - 415

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -